Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Neuropharmacology. 2015 Apr 2;95:353–360. doi: 10.1016/j.neuropharm.2015.03.029

Figure 4. Expression of GABABR-GIRK signaling components in the male and female mPFC.

Figure 4

A) mRNA levels of GABABR-GIRK signaling pathway constituents (GIRK1, GIRK2, GIRK3, GABABR1 and GABABR2) in micropunches containing the mPFC from adolescent male (M) and female (F) wild-type mice. Data are normalized to the expression of GAPDH and to mRNA levels in samples from male mice (n=4–6/sex). B) Top: representative immunoblots showing total protein levels of the key GABABR-GIRK signaling pathway constituents (G1: GIRK1, G2: GIRK2, G3: GIRK3, B1: GABABR1, B2: GABABR2, βAct: β-actin) in micropunches containing the mPFC from adolescent male (M) and female (F) wild-type mice. Bottom: quantification of GIRK and GABABR protein levels, with normalization to the levels of β-actin and to protein levels in samples from male mice (n=6/sex).